Literature DB >> 10773319

Changes in the outer capsid proteins of bluetongue virus serotype ten that abrogate neutralization by monoclonal antibodies.

C D DeMaula1, K R Bonneau, N J MacLachlan.   

Abstract

Six neutralizing monoclonal antibodies (Mabs) and nine neutralization resistant viral variants (escape-mutant viruses (EMVs)) were used to further characterize the neutralization determinants of bluetongue virus serotype 10 (BTV10). The EMVs were produced by sequential passage of a highly cell culture adapted United States prototype strain of BTV10 in the presence of individual neutralizing Mabs. Mabs were characterized by neutralization and immune precipitation assays, and phenotypic properties of EMVs were characterized by neutralization assay. Sequencing of the gene segments encoding outer capsid proteins VP2 and VP5 identified mutations responsible for the altered phenotypic properties exhibited by individual EMVs. Amino acid substitutions in VP2 were responsible for neutralization resistance in most EMVs, whereas an amino acid substitution in VP5, without any change in VP2, was responsible for the neutralization resistance of one EMV. The data confirm that VP2 contains the major neutralization determinants of BTV, and that VP5 also can influence neutralization of the virus. The considerable plasticity of the neutralization determinants of BTV has significant implications for future development of non-replicating vaccines.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10773319     DOI: 10.1016/s0168-1702(00)00130-1

Source DB:  PubMed          Journal:  Virus Res        ISSN: 0168-1702            Impact factor:   3.303


  21 in total

1.  Structural Protein VP2 of African Horse Sickness Virus Is Not Essential for Virus Replication In Vitro.

Authors:  René G P van Gennip; Sandra G P van de Water; Christiaan A Potgieter; Piet A van Rijn
Journal:  J Virol       Date:  2017-01-31       Impact factor: 5.103

2.  Occurrence of genetic drift and founder effect during quasispecies evolution of the VP2 and NS3/NS3A genes of bluetongue virus upon passage between sheep, cattle, and Culicoides sonorensis.

Authors:  K R Bonneau; B A Mullens; N J MacLachlan
Journal:  J Virol       Date:  2001-09       Impact factor: 5.103

3.  Characterization of C-strain "Riems" TAV-epitope escape variants obtained through selective antibody pressure in cell culture.

Authors:  Immanuel Leifer; Sandra Blome; Ulrike Blohm; Patricia König; Heike Küster; Bodo Lange; Martin Beer
Journal:  Vet Res       Date:  2012-04-20       Impact factor: 3.683

4.  Oncolytic bluetongue viruses: promise, progress, and perspectives.

Authors:  Joseph K-K Li
Journal:  Front Microbiol       Date:  2011-03-16       Impact factor: 5.640

5.  Identification and differentiation of the twenty six bluetongue virus serotypes by RT-PCR amplification of the serotype-specific genome segment 2.

Authors:  Narender S Maan; Sushila Maan; Manjunatha N Belaganahalli; Eileen N Ostlund; Donna J Johnson; Kyriaki Nomikou; Peter P C Mertens
Journal:  PLoS One       Date:  2012-02-28       Impact factor: 3.240

6.  An equine herpesvirus type 1 (EHV-1) expressing VP2 and VP5 of serotype 8 bluetongue virus (BTV-8) induces protection in a murine infection model.

Authors:  Guanggang Ma; Michael Eschbaumer; Abdelrahman Said; Bernd Hoffmann; Martin Beer; Nikolaus Osterrieder
Journal:  PLoS One       Date:  2012-04-12       Impact factor: 3.240

Review 7.  Adaptive strategies of African horse sickness virus to facilitate vector transmission.

Authors:  Anthony Wilson; Philip Scott Mellor; Camille Szmaragd; Peter Paul Clement Mertens
Journal:  Vet Res       Date:  2008-12-19       Impact factor: 3.683

8.  Establishment of a bluetongue virus infection model in mice that are deficient in the alpha/beta interferon receptor.

Authors:  Eva Calvo-Pinilla; Teresa Rodríguez-Calvo; Juan Anguita; Noemí Sevilla; Javier Ortego
Journal:  PLoS One       Date:  2009-04-09       Impact factor: 3.240

9.  Protection of IFNAR (-/-) mice against bluetongue virus serotype 8, by heterologous (DNA/rMVA) and homologous (rMVA/rMVA) vaccination, expressing outer-capsid protein VP2.

Authors:  Tamara Kusay Jabbar; Eva Calvo-Pinilla; Francisco Mateos; Simon Gubbins; Abdelghani Bin-Tarif; Katarzyna Bachanek-Bankowska; Oya Alpar; Javier Ortego; Haru-Hisa Takamatsu; Peter Paul Clement Mertens; Javier Castillo-Olivares
Journal:  PLoS One       Date:  2013-04-12       Impact factor: 3.240

10.  Identification and characterization of a novel non-structural protein of bluetongue virus.

Authors:  Maxime Ratinier; Marco Caporale; Matthew Golder; Giulia Franzoni; Kathryn Allan; Sandro Filipe Nunes; Alessia Armezzani; Amr Bayoumy; Frazer Rixon; Andrew Shaw; Massimo Palmarini
Journal:  PLoS Pathog       Date:  2011-12-29       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.